“Efficacy Comparison of Targeted Systemic Monotherapies Including Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: a Network Meta-Analysis” (2024) SKIN The Journal of Cutaneous Medicine, 8(1), p. s313. doi:10.25251/skin.8.supp.313.